Apellis Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Apellis Contact Number

Contact Us Apellis

1 hours ago Apellis.com Show details

(617) 977-5700Contact Us Apellis. Call Us. (617) 977-5700 Main Office. (833) 866-3346 (833-TO-MEDINFO) Medical Information Call Center. Addresses. Main Office. 100 5th Avenue. Waltham, MA 02451, USA. Watertown, MA.

Category: Contact SupportShow more

Official Home Page of the Apellis Pharmaceuticals

3 hours ago Apellis.com Show details

Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.

Category: Home PhoneShow more

Apellis Pharmaceuticals Crunchbase Company Profile & …

3 hours ago Crunchbase.com Show details

502-241-4114Contact Email [email protected]apellis.com Phone Number 502-241-4114 Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease.

Founded: 2008
Founders: Pascal Deschatelets, Cedric Francois

Category: Contact NumberShow more

Apelles About Us

5 hours ago Apellesnow.com Show details

Contact Us. Apelles is strategically positioned to support customers along the entire customer lifecycle. We provide tailored solutions to complement your business. Our relatively flat organizational structure allows our experienced team of professionals to be responsive to your needs. We are ready to partner with your organization.

Category: Contact NumberShow more

Apellis PNH Pioneer: Site Locations & Contact

8 hours ago Pnhpioneer.com Show details

Site Locations & Contact Connect with a research site to see if your adolescent may be eligible to participate in PIONEER. To connect with a PIONEER research site, select the location that is most convenient to you and then submit your contact information. The research site will follow-up with you within 10 business days.

Category: Contact SupportShow more

Privacy Policy for Apellis Pharmaceuticals Apellis

9 hours ago Apellis.com Show details

Contact information (personal and business), such as name, job title and employer name, email address, mailing address, phone number, and emergency contact information; Biographical and demographic information , such as age, date of birth, gender, marital status, ethnicity, and information regarding any parents or legal guardians;

Category: Contact NumberShow more

Apellis Information Apellis Profile

5 hours ago Rocketreach.co Show details

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Category: Contact NumberShow more

Apellis Pharmaceuticals Corporate Headquarters, Office

Just Now Craft.co Show details

Apellis Pharmaceuticals is headquartered in Crestwood, KY and has 4 office locations across 2 countries. See the full list at Craft.

Category: Contact NumberShow more

Apellis Email Format apellis.com Emails

Just Now Rocketreach.co Show details

Apellis uses 4 email formats, with first '.' last (ex. [email protected]apellis.com) being used 71.4% of the time. Get Verified Emails for Apellis Employees. Apellis's Email Format. Percentage.

Category: Contact NumberShow more

ANZCTR Registration

1 hours ago Anzctr.org.au Show details

Randomisation Numbers will be comprised of the letter R followed by a four-digit number of the format ‘Rprnn’, where p denotes the cohort number (i.e. for Cohort 1, p=1), r is a replacement indicator and nn is a sequential randomisation number, i.e. R1001, R1002, etc.

Category: Contact NumberShow more

Apellis Overview, News & Competitors ZoomInfo.com

4 hours ago Zoominfo.com Show details

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to three new employees …

Category: Contact NumberShow more

Apellis Pharmaceuticals, Inc.

2 hours ago Apellispharmaceuticalsinc.com Show details

At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease

Category: Contact NumberShow more

Apellis Grants and Giving Apellis.com

Just Now Apellis.com Show details

Grant requests must be submitted to [email protected]apellis.com with ample time (minimum of 60 days) before the activity start date to allow for processing and consideration by Apellis’s regional Grants Review Committees. The following information is required for all application submissions: Letter of Request (LOR) on organization’s letterhead, including Program/project …

Category: Contact NumberShow more

Apellis Pharmaceuticals Company Profile Office Locations

Just Now Craft.co Show details

Apellis Pharmaceuticals has 235 employees across 4 locations and $250.65 M in annual revenue in FY 2020. See insights on Apellis Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Category: Contact NumberShow more

Apellis Pharmaceuticals Inc Company Profile and News

9 hours ago Bloomberg.com Show details

Company profile page for Apellis Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information

Category: Contact NumberShow more

Apellis Pharmaceuticals, Inc. (APLS) Company Profile

5 hours ago Finance.yahoo.com Show details

See the company profile for Apellis Pharmaceuticals, Inc. (APLS) including business summary, industry/sector information, number of employees, business …

Category: Contact NumberShow more

CONTACT PIO

8 hours ago Pio.gov.cy Show details

Address by the President of the Republic, Mr Nicos Anastasiades, at the dinner in honour of the participants at the 2nd International Conference on Climate Change in the Eastern Mediterranean and Middle East

Category: Contact SupportShow more

SEC Filing Apellis Pharmaceuticals, Inc.

4 hours ago Investors.apellis.com Show details

(502) 241-4114Apellis Pharmaceuticals, Inc. 6400 Westwind Way, Suite A . Crestwood, KY 40014 (502) 241-4114 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to:

Category: Contact NumberShow more

Lukas Scheibler's email & phone number Chief Innovation

Just Now Signalhire.com Show details

View Lukas Scheibler's email address: [email protected]apellis.com & phone: +1-xxx-xxx-6692's profile as Chief Innovation Officer at Apellis Pharmaceuticals, located in Waltham, Massachusetts. Find contacts: direct phone number, email address, work experience.

Category: Phone NumberShow more

Apellis Pharmaceuticals Reports Second Quarter 2021

6 hours ago Investors.apellis.com Show details

(866) 774-0323Apellis will host a conference call and webcast to discuss its second quarter 2021 financial results and business highlights today, August 9, 2021, at 4:30 p.m. ET. To access the conference call, please dial (866) 774-0323 (local) or (602) 563-8683 (international) at least 10 minutes prior to the start time and refer to conference ID 5762347.

Category: Contact NumberShow more

Apellis Pharmaceuticals LinkedIn

Just Now Linkedin.com Show details

Apellis Pharmaceuticals 23,553 followers on LinkedIn. Global biopharma company leveraging courageous science, creativity, and compassion to deliver life-changing therapies. At Apellis

Category: Contact NumberShow more

SEC Filing Apellis Pharmaceuticals, Inc.

4 hours ago Investors.apellis.com Show details

Item 1.01. Entry into a Material Definitive Agreement. On May 6, 2020, Apellis Pharmaceuticals, Inc. (the “Company”) priced a private offering of $300.0 million aggregate principal amount of its 3.500% convertible senior notes due 2026 (the “notes”).

Category: Contact NumberShow more

Anil K. Rattan, Ph.D. Director of Global Quality

8 hours ago Linkedin.com Show details

View Anil K. Rattan, Ph.D.’s profile on LinkedIn, the world’s largest professional community. Anil K. has 2 jobs listed on their profile. See the complete profile on LinkedIn and discover Anil

Title: End-to-End GxP Phase …
Location: Waltham, Massachusetts, United States
1. 500+ connections

Category: Contact NumberShow more

EMPAVELI™ (pegcetacoplan) Start Form

3 hours ago Empavelihcp.com Show details

Contact Phone Number: Contact Email: Preferred Method of Contact: Phone Email Fax Patient Name: Date of Birth The purpose of this form is to permit Apellis Pharmaceuticals, Inc., its affiliates, representatives, agents, and contractors (“Apellis”) to provide

Category: Contact NumberShow more

Apellis Pharmaceuticals Announces Inducement Grants Under

7 hours ago Finance.yahoo.com Show details

212.600.1902Investor Contact: Argot Partners apellis@argotpartners.com +1 212.600.1902. Recommended Stories. Investor's Business Daily. Crispr Stock Follows Allogene's Path And Dives On Gene-Editing Test.

1. Author: Apellis Pharmaceuticals, Inc.

Category: Contact NumberShow more

Apellis names Thomas Lackner senior VP, head of Europe

4 hours ago Bizjournals.com Show details

Apellis Pharmaceuticals Inc. is expanding into Europe and has hired an executive to oversee those operations. Thomas Lackner joined Crestwood, Ky.-based Apellis as senior vice president, head of

Category: Contact NumberShow more

Apellis Pharmaceuticals Reports Second Quarter 2021

2 hours ago Finance.yahoo.com Show details

Apellis did not have any net product revenue in the quarter ended June 30, 2020. Research and development (R&D) expenses were $145.9 million in the second quarter of 2021, compared to $87.1

Category: Contact NumberShow more

A support program for people taking EMPAVELI

5 hours ago Empaveli.com Show details

The Apellis Bridge can help with interruptions or changes in insurance. If your insurance provider has changed or your plan has changed, you may experience an interruption in coverage. If this occurs, you could be eligible for a temporary supply of EMPAVELI through the Apellis

Category: Support NumberShow more

Apellis Pharmaceuticals Inc. (APLS) Upgraded Issued by

4 hours ago Newsheater.com Show details

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) went down by -3.26% from its latest closing price compared to the recent 1-year high of $73.00. The company’s stock price has collected -2.43% of loss in the last five trading sessions. Press Release reported on 08/09/21 that Apellis Pharmaceuticals Repor

Category: Contact NumberShow more

Apellis Pharmaceuticals to Host Conference Call on August

Just Now Finance.yahoo.com Show details

WALTHAM, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the

1. Author: Apellis Pharmaceuticals, Inc.

Category: Contact NumberShow more

MidDay Market Update: Crude Oil Rises Over 2%; Apellis

Just Now Finance.yahoo.com Show details

Midway through trading Friday, the Dow traded down 0.40% to 34,739.37 while the NASDAQ fell 0.06% to 15,238.92. The S&P also fell, dropping 0.21% to 4,483.84. The U.S. has the highest number of

Category: Contact NumberShow more

Nur Nicholson at Apellis Pharmaceuticals AroundDeal

Just Now Arounddeal.com Show details

Nur Nicholson is the Chief Technical Operations Officer at Apellis Pharmaceuticals based in United States.Known as a customer-focused business leader with broad pharmaceutical industry knowledge, I drive enterprise vision and strategy for innovative products and business solutions. I seize complex problems, often in demanding environments.

Category: Contact NumberShow more

How Do Analysts Perceive Apellis Pharmaceuticals Inc

4 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 80.65 million. APLS does have institutional investors; and they hold 76.50% of the stock. Apellis Pharmaceuticals Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 10 new insider purchases involving 41,858 shares.

Category: Contact NumberShow more

Apellis Pharmaceuticals Inc. (NASDAQ: APLS) Shares Have

4 hours ago Marketingsentinel.com Show details

Apellis Pharmaceuticals Inc. (NASDAQ:APLS)’s Major holders Insiders own 18.86% of the company shares, while shares held by institutions stand at 76.67% with a share float percentage of 94.49%. Investors are also buoyed by the number of investors in a company, with Apellis Pharmaceuticals Inc. having a total of 313 institutions that hold

Category: Contact NumberShow more

Apellis Pharmaceuticals Announces Private Placement of

8 hours ago Investors.apellis.com Show details

WALTHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it had entered into subscription agreements with a number of institutional investors for a private placement of $300.0 million aggregate principal amount of …

Category: Contact NumberShow more

Apellis Pharmaceuticals Inc. (APLS) May Have A Gold Mine

2 hours ago Stocksregister.com Show details

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) price on Friday, October 08, fall -1.07% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $33.19. A look at the stock’s price movement, the close in the last trading session was $33.55, moving within a rang

Category: Contact NumberShow more

Brian Jochim Sr. Director, Talent Acquisition & People

9 hours ago Linkedin.com Show details

Brian Jochim Head, Talent Acquisition & People Services at Apellis Pharmaceuticals Waltham, Massachusetts, United States 500+ connections

Title: Head, Talent Acquisition & …
Location: Waltham, Massachusetts, United States
1. 500+ connections

Category: Contact NumberShow more

Apellis Switzerland GmbH in Zug Reports Moneyhouse

3 hours ago Moneyhouse.ch Show details

200.662.403Apellis Switzerland GmbH is registered in the Canton of ZG under the UID CHE-200.662.403. EMOTIVE GmbH , Galderma SA , LKQ Europe GmbH have the same address as Apellis Switzerland GmbH. Management (6)

Category: Contact NumberShow more

Apellis Pharmaceuticals Number of Employees 20162021

Just Now Macrotrends.net Show details

Apellis Pharmaceuticals number of employees from 2016 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company.

Category: Contact NumberShow more

Apellis Pharmaceuticals (APLS) Option Chain Market Chameleon

4 hours ago Marketchameleon.com Show details

As a feature of Market Chameleon's option chain, you can view the list of option trades for each individual Apellis Pharmaceuticals (APLS) option by clicking on the corresponding volume number in the table above.It will bring up a display with the time and sales listed. On this display, you can see trade details, like time of the trade, price, condition, the trade's implied …

Category: Contact NumberShow more

Buy or Sell Apellis Pharmaceuticals Inc. (APLS) Stock Now

6 hours ago Newsheater.com Show details

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) went down by -3.45% from its latest closing price compared to the recent 1-year high of $73.00. The company’s stock price has collected -13.34% of loss in the last five trading sessions. Press Release reported on 08/09/21 that Apellis Pharmaceuticals Repo

Category: Contact NumberShow more

Apellis Pharmaceuticals Inc. (NASDAQ: APLS) Investors To

7 hours ago Marketingsentinel.com Show details

In the last trading session, 1.53 million Apellis Pharmaceuticals Inc. (NASDAQ:APLS) shares changed hands as the company’s beta touched 1.72. With the company’s per share price at $33.01 changed hands at -$0.58 or -1.73% during last session, the market valuation stood at $2.82B. APLS’s last pr

Category: Contact NumberShow more

APELLIS PHARMACEUTICALS, INC. : APLS Stock Price

6 hours ago Marketscreener.com Show details

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade.

Category: Contact NumberShow more

Apellis Pharmaceuticals Reports First Quarter 2021

5 hours ago Investors.apellis.com Show details

(866) 774-0323Apellis will host a conference call and webcast to discuss its first quarter 2021 financial results and business highlights today, April 28, 2021, at 4:30 p.m. ET. To access the conference call, please dial (866) 774-0323 (local) or (602) 563-8683 (international) at least 10 minutes prior to the start time and refer to conference ID 7883183.

Category: Contact NumberShow more

Apellis Pharmaceuticals Inc. (NASDAQ: APLS) Spiked 6.49%

4 hours ago Marketingsentinel.com Show details

Apellis Pharmaceuticals Inc. (NASDAQ:APLS)’s traded shares stood at 1.63 million during the last session, with the company’s beta value hitting 1.49. At the close of trading, the stock’s price was $64.18, to imply an increase of 4.17% or $2.57 in intraday trading. The APLS share’s 52-week hi

Category: Contact NumberShow more

Apellis eye drug succeeds in one key study, but falls

7 hours ago Biopharmadive.com Show details

Apellis eye drug succeeds in one key study, but falls short in its twin. A closely watched experimental treatment for a leading cause of blindness slowed the death of retinal cells in a large, late-stage study, a finding that the drug's maker, Apellis Pharmaceuticals, said Thursday will support an application to the Food and Drug Administration

Category: Contact NumberShow more

Why Apellis Pharmaceuticals Inc. (APLS)’s Most Recent

7 hours ago Newsheater.com Show details

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) went down by -37.19% from its latest closing price compared to the recent 1-year high of $73.00. The company’s stock price has collected -44.22% of loss in the last five trading sessions. Barron’s reported on 09/10/21 that Apellis Stock Plunges Afte

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of company is apellis pharmaceuticals?

We are a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies.

What do you need to know about apellis empaveli?

Please see full Prescribing Information, including Boxed WARNING and Medication Guide. complement-driven diseases. Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

What are the latest results from apellis Prince study?

Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH At the heart of our company is the belief that exceptional science and compassion are not mutually exclusive.

What kind of gene therapy does apellis use?

Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD), and Gene Therapy San Francisco, California 94102, US Love is love!

Popular Brands

Amazon
Abbvie
Aia
Asml
Att
Amgen
Apple
Adobe
Aptar
Acc
Adidas
Aak
Aes